News
Archive
Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735
Cambridge Epigenetix names Peter Fromen as Chief Executive Officer
Phase Four and Impulse Space to collaborate on multi-mode propulsion
Vascular Therapies completes $25 million private financing
Introducing Avari Wireless, a state-of-the-art designer & manufacturer of public safety DAS
Paragraf raises $60 million in Series B financing
Back To News

October 17, 2017
Trellis Bioscience
Developer of CellSpot platform to derive therapeutic antibodies directly from the human immune system.